DEALS AND M NEWS
- Shaky spear? Bard in play for CKD with new wisdom as phase II/III trial begins
- Fusion energized in targeted radiotherapy effort with $25M series A
- Toolgen's AAV delivery could move CRISPR/Cas9 beyond genetic disease
- China's drug reforms will gain traction, but changes are slow
- PMV Pharma raises $74M series B for p53-focused ...
- Beijing's Apollobio to bring Inovio's new HPV drug to China marketplace
- Chi-Med's savolitinib hits phase II endpoints in Met-driven PRCC
- Samsung's biosimilars come to fruition despite scandals, company says
- Germline gene editing should be allowed – in certain situations
- Tivantinib misses OS endpoint in phase III liver...
Cast Your Vote
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.